updated 2/4/2011 8:16:42 AM ET 2011-02-04T13:16:42

SOUTH SAN FRANCISCO, Calif., Feb. 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that CEO Peter J. Langecker, M.D., Ph.D., will present a corporate overview and update at the BIO CEO and Investor Conference on Monday, February 14th, at 1:30 p.m. EST (10:30 a.m. PST), in the Waldorf-Astoria Hotel's Conrad Suite in New York City, NY. An archived webcast of the presentation can be accessed for 30 days following the presentation under the Investor Center tab at www.oxigene.com .

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

CONTACT: Investor and Media Contact:
         Michelle Edwards, Investor Relations
         medwards@oxigene.com
         650-635-7006

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.94%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com